Latest "IN VITRO DIAGNÓSTICA S/A" News Stories

01:57 EDT 21st July 2018 | BioPortfolio

Here are the most relevant search results for "IN VITRO DIAGNÓSTICA S/A" found in our extensive news archives from over 250 global news sources.

More Information about IN VITRO DIAGNÓSTICA S/A on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about IN VITRO DIAGNÓSTICA S/A for you to read. Along with our medical data and news we also list IN VITRO DIAGNÓSTICA S/A Clinical Trials, which are updated daily. BioPortfolio also has a large database of IN VITRO DIAGNÓSTICA S/A Companies for you to search.

Showing "VITRO DIAGN STICA" News Articles 1–25 of 758

Friday 20th July 2018

FDA grants Breakthrough Device Designation for Roche's Elecsys cerebrospinal fluid (CSF) assays to support the improved diagnosis of Alzheimer's disease

F. Hoffmann-La Roche Ltd / FDA grants Breakthrough Device Designation for Roche's Elecsys cerebrospinal fluid (CSF) assays to support the improved diagnosis of Alzheimer's disease . Processed and transmitted by Nasdaq Corporate Solutions. The issuer is solely responsible for the content of this announcement. Basel, 20 July 2018 - Roche (SIX: RO, ROG; OTCQX: RHHBY) ann...

Thursday 19th July 2018

Y-BRUSH, The Only 10-Second Toothbrush Which Has Proven Its Efficacy

Not just another high-tech gadget, Y-Brush is a real innovation able to clean your teeth 12 times faster than a standard toothbrush thanks to a proven technology and intensive work in R&D in cooperation with dentists. Almost a third of Americans have admitted to brushing their teeth less than twice a day, and on average they don't brush thei...

Innovus Pharma Signs Purchase Agreement with CVS Pharmacy, Inc. to Sell Its Product Androferti® to Increase Sperm Quality in Their Newly Established In-Store Men’s Clinic

CVS Men’s Health Clinic Pilot Program to Promote Androferti® in 12 to 20 Stores with the Potential, if Successful, to Expand Nationwide and Add Additional Products Innovus Pharmaceuticals, Inc. (“Innovus Pharma” or the “Company”) (OTCQB Venture Market: INNV), an emerging commercial-stage pharmaceutical company that delivers safe, innovative ...

FIV : C’est déjà 8 millions de naissances

40 ans après la naissance de Louise Brown, le premier bébé éprouvette, on peut bien parler de succès : plus de 8 millions de bébés nés de la FIV depuis 1978 sont à mettre au crédit de la fécondation in vitro. Et les taux de grossesse avec la FIV se stabilisent en Europe autour de 36%, […]

Wednesday 18th July 2018

A Third of U.S. Adults Say They Have Used Fertility Treatments or Know Someone Who Has

(Pew Research Center) – Four decades after the birth of Louise Brown, the first “test-tube baby” conceived via in vitro fertilization (IVF), 33% of American adults report that they or someone they know has used some type of fertility treatment … Read More

Complex Knee Surgeon Robert LaPrade, MD, PhD, and Colleagues Selected for Four Awards at the 2018 American Orthopaedic Society for Sports Medicine Annual Meeting

Dr. Robert LaPrade and colleagues at the Steadman Philippon Research Institute were honored with four awards for their cutting-edge research in key areas of orthopaedic sports medicine. VAIL, Colo. (PRWEB) July 18, 2018 Complex knee surgeon, Robert LaPrade, MD, PhD, and colleagues at the Steadman Philippon Research Institute (SPRI) were selected for four awards at the 2018 American Orthopedic Soc...

Tuesday 17th July 2018

Fatty liver disease pandemic needs 'gold standard' human-relevant research

(Humane Society International) New study calls for human-based tools to unravel the pathogenesis of non-alcoholic steatohepatitis (NASH). The contribution of in silico, in vitro and pathways-based systems biology approaches to unraveling the pathogenesis of this disease are described, and how this human-relevant research can be used for anti-NASH drug development.

Catalent Experts to Discuss Oral Peptide Delivery and Advanced Modelling to Optimize Formulation at Upcoming Controlled Release Society Conference

Catalent Pharma Solutions, the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced that its scientific and formulation experts will be attending and contributing to the educational agenda at the upcoming Controlled Release Society (CRS) Annual Meeting and Exposition, to be held at the New York Hilton...

Co-Diagnostics Completes Submission of CE Mark Registration for Tuberculosis Screening Test

Company’s Logix Smart™ MTB Test to be available for purchase with CE mark in August 2018 Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, proprietary platform for the development of molecular diagnostic tests, announced today that its Logix Smart™ MTB Test technical file has been submitted for registra...

Inflection Biosciences Announces Publication of Positive Data for Dual Mechanism Inhibitor Against Chronic Lymphocytic Leukaemia

Inflection Biosciences Ltd, a private company developing innovative therapeutics for cancer, today announced the publication of preclinical data showing the company’s dual mechanism PIM/PI3 kinase inhibitor IBL-202 has promise as a treatment for chronic lymphocytic leukaemia (CLL). This research has been published in the most recent issue of the p...

Monday 16th July 2018

Drug-filled nanobubbles triggered by X-rays

The tiny bubbles, known as liposomes, are commonly used in pharmacology to encapsulate drugs, making them more effective in the treatment of disease. As explained by Dr Wei Deng, an associate investigator at the CNBP, “The development and application of various nanomaterial designs for drug delivery is currently a key focus area in nanomedicine. “Liposomes are already well established as an e...

Eurobio Scientific acquires Dendritics, a company specializing in antibody development and manufacture

Eurobio Scientific acquires Dendritics,  a company specializing in antibody development and manufacture This strategic acquisition strengthens the Group's offer for the life sciences market                                    Paris, July 16, 2018 - 5.45 pm Eurobio Scientific (FR0013240934, ALERS, eligible PEA-PME), leading French grou...

Amerigroup Medicare Solutions Center Opens in Houston’s International District

Amerigroup Medicare Solutions Center helps consumers understand their Amerigroup Medicare health insurance options and offers support in English and Vietnamese The Amerigroup Medicare Solutions Center recently opened in the International District to deliver a high level of support to consumers who are exploring their Medicare health insurance options, ...

Eppendorf introduces first ready-to-use, synthetic cell cultureware for iPSC and MSC stem cells

Since the groundbreaking discovery of human induced pluripotent stem cells (hiPSCs) by Shinya Yamanaka in 2006, the use of pluripotent stem cells (PSCs) has experienced a boom. Due to their extensive in vitro self-renewal properties and their ability to differentiate into many different cell types, PSCs, and especially hiPSCs, offer exciting promises....

Sunday 15th July 2018

AIT Therapeutics Announces Human and In-Vitro Nitric Oxide (NO) Data Presented at the 3rd Annual World Bronchiectasis Conference

Presentations highlighted the direct killing effect of NO on Mycobacterium abscessus (M. abscessus) and Pseudomonas aeruginosa (P. aeruginosa) as well as the use of the NO generator and delivery system as a potential therapy for M. abscessus complex (MABSC) lung infection GARDEN CITY, N.Y., and REHOVOT, Israel, July 16, 2018 (GLOBE NEWSWIRE) --  AIT Therapeutics, Inc. (OTC:AITB), a clinical-...

Saturday 14th July 2018

Metabolic vulnerability of cisplatin-resistant cancers

Cisplatin is the most widely used chemotherapeutic agent, and resistance of neoplastic cells against this cytoxicant poses a major problem in clinical oncology. Here, we explored potential metabolic vulnerabilities of cisplatin-resistant non-small human cell lung cancer and ovarian cancer cell lines. Cisplatin-resistant clones were more sensitive to killing by nutrient deprivation in vitro an...

Friday 13th July 2018

Study: Women's emotional state not related to success of infertility treatment

Infertility treatments, such as In-vitro fertilization, are stressful experiences for women that can take large emotional tolls, especially when the treatment fails.

Cancer Drug Effectiveness Evaluated Using New Methodology

Researchers report the development of a technique that allows them to measure how well cancer drugs reach their targets inside the body. It shows individual cancer cells in a tumor in real time, revealing which cells interact with the drug and which cells the drug fails to reach, according to the scientists. In the future, the findings (“ Heterogeneity in tumor chromatin-doxorubicin binding ...

New Method Developed to Help Determine Effectiveness of Cancer Drugs

Researchers report the development of a technique that allows them to measure how well cancer drugs reach their targets inside the body. It shows individual cancer cells in a tumor in real time, revealing which cells interact with the drug and which cells the drug fails to reach, according to the scientists. In the future, the findings (“ Heterogeneity in tumor chromatin-doxorubicin binding ...

Thursday 12th July 2018

Human Antibody for Deploying CH2-Based Therapeutics

The National Cancer Institute seeks parties to license fully human antibodies for CH2-based research materials. Recently, isolated immunoglobulin constant CH2 domains were proposed as scaffolds for construction of libraries containing diverse binders that could confer some effector functions.  As a fragment in all IgGs, which are at high concentrations in blood, CH2-based therapeutics are likely ...

Improved Production of Prenylated Protein in Insect Cells

KRAS and other Ras-family enzymes are an important component of over 30% of human cancers, however, no effective therapeutics targeting Ras or Ras-driven cancers are currently available.  The production of Ras proteins in vitro is required for the identification and characterization of Ras targeting drugs.  An important step in producing the Ras protein involves prenylation of the C-terminus of ...

PARP Inhibitor and NO-Donor Dual Prodrugs as Anticancer Agents

Poly-ADP ribose polymerase-1 (PARP-1) is a critical enzyme involved in DNA repair.  The inhibition of PARP has emerged as a promising strategy in cancer therapy.  Numerous PARP inhibitors have been developed and advanced into clinical trials, both for use as single agents in specific patient populations and as combination therapies with various chemotherapeutics.  The induction of strand break ...

Fully-human Monoclonal Antibodies Against Human EphrinB2 and EphB4

Ephrin receptor tyrosine kinases and their ephrin ligands have been implicated in cancer pathogenesis. Ephrin receptors and ligands affect tumor growth, invasiveness, angiogenesis, and metastasis. Ephrin signaling activities in cancer are complex and are only now beginning to be uncovered. Researchers at the National Cancer Institute-Frederick, NIH developed a set of five fully-human monoclonal a...

BODIPY-FL Nilotinib (Tasigna) for Use in Cancer Research

The National Cancer Institute''s Laboratory of Cell Biology is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize bodipy conjugated tyrosine kinase inhibitors that are currently used in the clinic for the treatment of CML or gastric cancers. We are also interested in evaluating third generation tyrosine kina...

Synergistic Combination Agent for Cancer Therapy

Work by the Nanotechnology Characterization Laboratory (NCL), a joint initiative of NCI, NIST, and the FDA, has led to the discovery of a novel combination chemotherapy. This combination is shown to have synergistic effects on cytotoxicity to cancer cells in vitro, and to cause a substantial decrease in tumor growth in preclinical tumor models in vivo. Combination therapy using these agents may en...

Quick Search


News Quicklinks